To OTC Journal Members:

There was simply too much great and not so great stuff to cover today. I just had a look at the BrandPartners (OTC BB: BPTR) Q1 earnings and I want to puke. On the other hand, Bad Toys, Advanced Cellular, and US Energy are looking great. Please read today's side bars. I'm trying to get it all to you.
 

Advanced Cellular (OTC BB: ACTC): Path To the Clinic Spelled Out

In case you haven't noticed, the market has been tanking for the last three days. Everything is selling off across the board- oil, gold, tech, health care, transports, biotech- pretty much everything; Except Advanced Cellular. Why?

A lot of investors are interested in this fairly obscure company by Wall Street standards. Early investors in Geron (NASDAQ: GERN) made a killing when the stem cell sector was hot. The founder of Geron is the Chief Scientist at ACTC now, and some are looking for a repeat performance.

ACTC has the potential to differentiate itself from the rest of the Stem Cell industry through its proprietary custom tailored Stem Cell development program. The company has developed stem cell technology wherein they can actually infuse a human egg with your DNA, and through a very complicated process, can create a Stem Cell line custom tailored for you. The process works on an unfertilized egg, and the egg is still viable after the procedure, thereby mitigating any potential moral objections. The possibilities boggle the mind. Since I'm rapidly falling apart at the age of 52, I might get them started on my Stem Cell line right now (just kidding, but not a bad idea).

So, if the market is pretty much collapsing, why is ACTC defying gravity and continuing a wonderful rebound? Today's press release post close might offer a clue.

After the market closed today, ACTC announced the "Path To the Clinic". It is already public knowledge that ACTC is focusing its therapy development on three applications for Stem Cell technology: vision restoration for certain eye diseases, dermal repair (burn victims), and cardio (heart repair) problems.

The timetable is laid out as follows. Apparently, one can assume ACTC is farthest along with its macular degeneration or eye disease program. The company expects to file its Investigational New Drug ("IND") application in a little over one year- in the second half of 2007. INDs for the other two therapies are expected to come in 2008.

You might think to yourself this seems a long ways off. Our major concern- how will the stock behave? Biotech company stock values tend to be effected by three major factors: 1. Clinical studies and their results and publications 2. The Regulatory progress 3. The market's appetite for biotech. When the biotech bubble inflates, all ships tend to rise with the tide. 

When the market refocuses its attention on Stem Cell companies- look out above.

In the interim, my suspicions are the market will like the announcement of a timetable with a path to the clinic. Many investors have been anxiously awaiting their calendar. The stock has been defying gravity of late, and I'll bet it continues tomorrow.

Also- don't forget about the predictable monthly downturn. Fund managers have the ability to sell $750,000 worth of stock every month. Look to accumulate on the monthly dip.

Here's today's press release for your review:
 

Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

Go Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketByte LLC has been paid a fee of $45,000 and 400,000 newly issued, restricted shares by US Energy Initiatives for coverage of the company. MarketByte LLC has been paid a fee of $30,000 and 250,000 warrants, exercisable at $2.54, by Advanced Cell Technology for coverage of the company. MarketByte LLC has been paid a fee of $25,000 and 150,000 newly issued restricted shares by Bad Toys for coverage of the company.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services.

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $140,0000 in Dutchess Private Equities II LP (“the Dutchess Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner. The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $190,0000 in the Longview Fund (“the Longview Limited Partnership”), both limited partnerships in which the MarketByte Pension Plan is a limited partner. No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Dutchess Limited Partnership or the Longview Fund.  The Dutchess Limited Partnership is one of two hedge funds managed by Dutchess Advisors.  Dutchess Advisors and Longview periodically refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter.  Dutchess Advisors or Longview may or may not own shares in the companies that it so refers to MarketByte. MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Dutchess Advisors or Longview owns any shares in the companies that it refers to MarketByte LLC.  The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies. 

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.  MarketByte LLC's mailing address is 3525 Del Mar Heights Rd #334, San Diego, CA 92130.